AngioDynamics (Nasdaq: ANGO) is expected to report Q4 earnings on July 11. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AngioDynamics's revenues will expand 49.9% and EPS will wither -40.0%.

The average estimate for revenue is $86.5 million. On the bottom line, the average EPS estimate is $0.06.

Revenue details
Last quarter, AngioDynamics logged revenue of $81.6 million. GAAP reported sales were 57% higher than the prior-year quarter's $51.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.08. GAAP EPS were -$0.03 for Q3 compared to -$0.07 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 50.3%, 670 basis points worse than the prior-year quarter. Operating margin was 7.1%, 430 basis points better than the prior-year quarter. Net margin was -1.2%, 220 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $338.5 million. The average EPS estimate is $0.33.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 99 members out of 113 rating the stock outperform, and 14 members rating it underperform. Among 35 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give AngioDynamics a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is outperform, with an average price target of $13.10.

Is AngioDynamics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.